NN-6581
- Generic Name
- NN-6581
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
Phase 1
Recruiting
- Conditions
- Healthy VolunteersHepatic Steatosis
- Interventions
- Drug: Placebo (NNC0581-0001)
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT06891365
- Locations
- 🇬🇧
Parexel CPRU, Level 7, Harrow, United Kingdom
First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases
Phase 1
Active, not recruiting
- Conditions
- Healthy VolunteersHepatic Steatosis
- Interventions
- Drug: Placebo (NNC0581-0001)
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT05599945
- Locations
- 🇬🇧
Parexel Research Unit, Harrow, Middlesex, United Kingdom
🇬🇧Parexel CPRU, Level 7, Harrow, Middlesex, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath